Published: October 13, 2025, 22:10 EDT

AstraZeneca has reached an agreement with the Trump administration to lower prescription drug prices for Medicaid, marking a significant move in the administration’s ongoing effort to make medicines more affordable. The deal, announced Friday at the White House, also spares the British drugmaker from potential tariffs threatened by President Donald Trump.

White House Announces Agreement With AstraZeneca

President Trump, alongside AstraZeneca Chief Executive Pascal Soriot, unveiled the agreement in the Oval Office. The arrangement will allow Medicaid to receive “most-favored-nation” pricing—ensuring that the U.S. government pays no more than the lowest price offered in comparable developed nations.

“For many years, Americans have paid the highest prices in the world for prescription drugs, by far,” Trump said during the announcement. “This deal will cut prices to the lowest level anywhere in the world—that’s what we get.”

Soriot described the negotiations as “tough but productive,” noting that the administration’s persistence pushed the company toward a comprehensive solution.

Part of Broader Push to Lower Prescription Costs

The AstraZeneca deal follows a similar agreement made by Pfizer last month, both stemming from a May executive order requiring drugmakers to reduce prices voluntarily or face federal payment restrictions. The policy has been described by the administration as an incentive-based approach to reforming pharmaceutical pricing.

Trump said tariffs played a key role in bringing companies to the table. “The tariffs were a big reason he came here,” he said, referring to Soriot.

Policy experts and consumer advocates have cautiously welcomed the development but warned that structural safeguards are needed to ensure long-term affordability rather than temporary reductions driven by executive action.

AstraZeneca’s Expanding U.S. Presence

Headquartered in Cambridge, United Kingdom, AstraZeneca is known for its portfolio of cancer treatments, including Tagrisso (lung cancer), Lynparza (ovarian cancer), and Calquence (chronic lymphocytic leukemia). Together, those drugs generated over $7.5 billion in U.S. sales last year, according to company data.

As part of its long-term U.S. investment strategy, AstraZeneca announced a $4.5 billion manufacturing facility near Charlottesville, Virginia. Virginia Governor Glenn Youngkin joined the Oval Office event to celebrate the project, which is expected to generate 3,600 new jobs in its initial phase.

The company said the Virginia plant is central to its $50 billion investment plan in the United States through 2030. AstraZeneca aims to reach $80 billion in annual revenue by that time, with roughly half coming from the U.S. market.

Political and Industry Reactions

President Trump credited his administration’s policies for encouraging major drugmakers to agree to voluntary cost reductions. He also criticized Democrats for attempting to claim political credit for similar pricing reforms initiated during the Biden administration.

One of AstraZeneca’s cancer drugs had already seen a price adjustment under Medicare negotiations launched during President Biden’s term. Despite that, Trump insisted the new agreement reflects his administration’s distinct approach to direct negotiation with pharmaceutical companies.

Economic analysts have noted that AstraZeneca’s decision to cancel an earlier vaccine facility expansion in the U.K. may have influenced its pivot toward deeper U.S. investments, citing favorable tax and regulatory conditions under the current administration.

Launch of TrumpRX.gov for Direct Drug Purchases

The White House also previewed a new online platform, TrumpRX.gov, designed to allow Americans to purchase medications directly from manufacturers. The website, set to launch in January 2026, will initially feature drugs from Pfizer and AstraZeneca.

According to officials, the portal aims to streamline pharmaceutical distribution by reducing intermediaries and ensuring lower retail prices for consumers.

The TrumpRX.gov landing page currently displays large photos of President Trump and a “Coming Soon” banner, along with a note stating it was “Designed in DC by The National Design Studio,” a government web design hub created in August and led by Airbnb co-founder Joe Gebbia.

Analysts Say Broader Implications Still Unclear

Economists and public health experts say the AstraZeneca deal represents progress toward lowering drug costs, but its long-term impact will depend on enforcement and continued cooperation between the federal government and pharmaceutical firms.

“If these price guarantees are maintained beyond the current administration, it could mark a turning point in U.S. healthcare affordability,” said Sarah Bloom, a senior analyst at the Brookings Institution. “But sustained oversight will be critical to prevent prices from rebounding once political pressure subsides.”

Source: AP News – AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

The post AstraZeneca Reaches Deal With Trump Administration to Lower U.S. Drug Prices appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

By [Your Name] | Updated June 2, 2025

At a White House event on Monday, former President Donald Trump signed an executive order aimed at lowering prescription drug prices in the U.S.—but not without making a controversial claim. According to Trump, other countries are the reason Americans pay more for their medications.

“We were subsidizing others’ healthcare,” Trump said. “They pay a small fraction for the same drug. The European Union has been brutal. But we’re not going to tolerate profiteering and price gouging anymore.”

It’s a powerful statement, but experts say the facts simply don’t support it.

THE CLAIM:

Trump argues that the U.S. is essentially “subsidizing” cheaper drug prices in countries like those in the EU by paying many times more for the same medications.

THE FACTS: It’s a U.S. System Problem, Not a Foreign One

Yes, Americans pay more for prescription drugs. In fact, much more.

A 2024 RAND Corporation report found that U.S. drug prices were, on average, 2.78 times higher than those in 33 other high-income countries. Brand-name drugs account for most of the gap. The U.S. represented a massive 62% of global drug sales—but only 24% of actual drug volume.

So why the huge difference? Experts say it’s not because other countries are exploiting the U.S., but because of how America’s fragmented pricing system works.

“There are structural differences in the way that we price drugs in the United States,” said Mariana Socal, a health policy expert at Johns Hopkins. “Those differences are what drive the price gap.”

How Drug Pricing Works in the U.S. vs. Abroad

In most countries, a single national agency negotiates drug prices on behalf of everyone. That gives them enormous leverage. In the U.S., by contrast, pricing is negotiated separately by dozens of private insurers and pharmacy benefit managers (PBMs)—a setup that weakens bargaining power and drives up costs.

“Anything that increases negotiating power—like covering more people—puts downward pressure on prices,” explained Courtney Yarbrough, a health policy professor at Emory University.

This isn’t new. It’s the reason drug companies often push higher prices in the U.S. while accepting lower profits elsewhere. A smaller margin overseas is better than no access at all.

What Does Trump’s Executive Order Actually Do?

Trump’s order sets a 30-day deadline for drugmakers to voluntarily lower prices in the U.S. If they don’t, a new “most favored nation” pricing rule would be drafted, tying U.S. drug prices to the lowest prices in similarly developed countries.

It sounds tough, but it’s unclear how much it will affect people with private insurance, since the federal government’s control mainly extends to Medicare and Medicaid.

And no—if U.S. prices drop, other countries won’t automatically start paying more. Experts say those countries may instead cut quiet deals or negotiate steeper discounts behind closed doors.

“We’re not in a static global pharmaceutical market,” Yarbrough added.

Why Drug Prices Stay High: It’s Not Just About Foreign Nations

The real story behind high drug prices in the U.S. has more to do with corporate incentives and market exclusivity. Manufacturers, PBMs, and wholesalers all benefit financially from higher list prices. Many companies also use patents strategically to delay cheaper generics from entering the market.

“There are no saints in this industry,” said Geoffrey Joyce, health policy director at USC’s Schaeffer Center. “Everyone makes more money off of higher list prices, so they keep pushing them up.”

While Trump threatened investigations into Big Pharma at the same press event, he also offered a surprisingly friendly defense of the industry—blaming other nations for their pricing tactics instead.

BOTTOM LINE:

The U.S. isn’t subsidizing other countries’ healthcare. Americans pay more for prescription drugs largely because of how the U.S. market is structured, not because of any unfair pressure from Europe or elsewhere. Trump’s executive order may aim to tackle the issue, but blaming other countries misses the mark.

Source: AP News – FACT FOCUS: Trump blames other countries for high US drug prices. Experts say it’s not their fault

The post Fact Check: Are Other Countries to Blame for U.S. Drug Prices? appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.